- Sterling Pharma Solutions will acquire and operate Novartis Ringaskiddy Limited Pharmaceutical Facility, located in Cork, Ireland
- This agreement foresees the continued provision of manufacturing, in a number of key areas, like cardiology, immunology, and oncology to Novartis
- Novartis and Sterling expect the transaction to be formally closed in the fourth quarter of 2022
- Sterling has a long-term strategy to invest in the Ringaskiddy site, developing more capacity and capabilities to attract customers from across the globe
Ringaskiddy, March 1, 2022 — Novartis announced today that it has reached an agreement with Sterling Pharma Solutions (Sterling), a leading global development and manufacturing company, to divest Novartis Ringaskiddy Limited Pharmaceutical facility (NRL), located in Cork, Ireland. The transaction is expected to be formally closed by both parties in the fourth quarter of 2022.
As part of the agreement, Sterling will produce medicines in Ireland for Novartis. This move is a continuation of the site's transformation journey to support a more sustainable future. The agreement with Sterling will secure the continued manufacturing of medicines and significant expertise in Ringaskiddy.
Sterling was selected, following an in-depth assessment process to identify the best fit for Novartis in terms of quality, services, culture and values, and to secure a sustainable future for the NRL associates.
Maeve Byrne, NRL Managing Director said, “We are very proud of our colleagues, who have achieved an excellent reputation for high quality, reliable production over the last 27 years. We are pleased to have secured the continued manufacturing of Novartis medicines in Ringaskiddy by Sterling, as well as to support the sustainability of jobs with significant expertise.”
Audrey Derveloy, Country President of Novartis in Ireland said, “It has been a source of great pride over the years to be able to tell medical practitioners that many Novartis products are made right here in Ireland. I would like to thank all our colleagues at Novartis Ringaskiddy for their ongoing commitment, and to assure them that we will support them throughout the transition process.”
The Ringaskiddy Campus will continue to play an important role in producing medicine for Novartis. The site has recently secured a 16 million US dollar investment from Novartis to manufacture a strategic raw material for a significant cardiovascular medicine. Sterling will also manufacture Novartis medicines in the areas of immunology and oncology on the site.
About Novartis Ireland
There are approximately 110,000 people working for Novartis around the world. Novartis Ireland currently employs about 1,500 people across three locations in Cork and Dublin. Novartis manufacturing (NRL) is based in Ringaskiddy (Cork) and is part of Novartis Technical Operations (NTO). There are approximately 400 NRL associates working in manufacturing at the Ringaskiddy site. NIS (Novartis Integrated Services) will continue to be hosted on the Ringaskiddy Campus. The Innovative Medicines Division (Pharmaceuticals), the Novartis Global Service Center (NGSC), and Novartis Gene Therapies are located in Dublin. Find out more at: Novartis Ireland
About Sterling Pharma Solutions (Sterling)
Sterling Pharma Solutions is a global contract development and manufacturing organisation (CDMO) with more than 50 years of experience in providing small molecule API (Active Pharmaceutical Ingredient) development and manufacturing services to the pharmaceutical industry, specializing in handling challenging chemistries. Sterling manages the most complex API and API intermediate challenges from proof-of-concept to commercial manufacture. Sterling has four facilities employing more than 850 people: its HQ in Dudley, Northumberland, UK; a dedicated bioconjugation and ADCs facility in Deeside, North Wales, UK; and two sites in the US, in Cary, North Carolina and Germantown, Wisconsin. Find out more www.sterlingpharmasolutions.com
Media contact :
AM O’Sullivan PR
Mobile: +353 087 988 1890
Head Country Communications, Novartis Ireland
Mobile: +353 86 224 8381